A gene therapy that has allowed several children born deaf to hear for the first time is being hailed as a “game changer” that raises hopes of the first new treatment for hereditary deafness in decades.
Several medical teams around the world are trialling the procedure, which focuses on a rare genetic mutation that affects only a small number of the 26 million people with congenital deafness globally.
However, several success stories announced last week are being seen as a turning point.
Photo: Children’s Hospital of Philadelphia via AP
On Tuesday last week, the Children’s Hospital of Philadelphia in Pennsylvania revealed that 11-year-old Aissam Dam, who was born deaf, was now “literally hearing sound for the first time in his life.”
Aissam still has mild-to-moderate hearing loss and might never learn to talk because the brain’s window for acquiring speech closes around the age of five.
However, a trial in China, the results of which were announced in The Lancet journal on Thursday, tested a similar treatment on six younger children.
Five gained the ability to hear, according to the findings of the trial that started in 2022, making it the first to have tested the gene therapy on humans.
Some of the children were already able to speak thanks to a cochlear implant — which they now no longer need, study coauthor Zheng-yi Chen of the Massachusetts Eye and Ear hospital said.
However, one, a baby only a year old, had never been able to communicate verbally, Chen said.
Chen said that after the treatment, when the mother asked the baby “Who am I?” the baby responded: “Mama.”
When asked what a chicken sounds like, the baby responded: “Coo-coo.”
“Everyone just cried with joy, it’s really amazing,” Chen said, adding that the baby was expected to grow up speaking normally.
Not since cochlear implants were invented 60 years has there been such an advance, Chen said, adding that the therapy “symbolizes a new era in the fight against all types of hearing loss.”
For now, the trials in China, the US and another announced in France this week all use a similar technique to focus on people born with a mutation of the OTOF gene.
This defect means they can no longer produce the protein otoferlin, which is needed for hair cells in the inner ear to convert sound vibrations into electrical signals that can be sent to the brain.
The treatment involves injecting a harmless virus into the inner ear that smuggles in a working version of the OTOF gene, restoring hearing.
The French trial is to focus on babies aged 12 months to 31 months, in the hopes it can “enable the acquisition of language”, said Nawal Ouzren, CEO of the firm Sensorion developing the treatment.
Natalie Loundon, a French doctor and hearing loss expert, called the technique “a game changer, a technological advance that will revolutionize therapeutic care.”
“The idea is to be able to offer this treatment to children rather than an implant, which is not always received well,” she said.
For the China-based trial, the researchers are to continue to study the participants to find out if their improved hearing lasts.
Chen estimated that the treatment tested in that trial could be ready to apply for regulatory approval within three to five years.
However, this particular treatment could only help a fraction of those born deaf.
About one in every 1,000 children are born deaf due to gene defects, but a lack of otoferlin is the cause of only about three percent of those cases.
More than 150 other genes have been discovered that trigger genetic hearing loss.
However, Chen had some good news.
So far, the otoferlin treatment seems to work just as well in humans as it did in during trials on mice — which is not always the case for such research.
Trials on mice targeting other gene defects that cause hearing loss have also been successful, Chen said.
Researchers therefore hope this first treatment opens the door to others.
Pasteur Institute in Paris, which pioneered the research on otoferlin, and Sensorion are already working on another therapy that focuses on a gene whose mutations are responsible for the most common forms of hereditary deafness.
The Philippine Department of Justice yesterday labeled Vice President Sara Duterte the “mastermind” of a plot to assassinate the nation’s president, giving her five days to respond to a subpoena. Duterte is being asked to explain herself in the wake of a blistering weekend press conference where she said she had instructed that Philippine President Ferdinand Marcos Jr be killed should an alleged plot to kill her succeed. “The government is taking action to protect our duly elected president,” Philippine Undersecretary of Justice Jesse Andres said at yesterday’s press briefing. “The premeditated plot to assassinate the president as declared by the self-confessed mastermind
Texas’ education board on Friday voted to allow Bible-infused teachings in elementary schools, joining other Republican-led US states that pushed this year to give religion a larger presence in public classrooms. The curriculum adopted by the Texas State Board of Education, which is controlled by elected Republicans, is optional for schools to adopt, but they would receive additional funding if they do so. The materials could appear in classrooms as early as next school year. Republican Texas Governor Greg Abbott has voiced support for the lesson plans, which were provided by the state’s education agency that oversees the more than
Ireland, the UK and France faced travel chaos on Saturday and one person died as a winter storm battered northwest Europe with strong winds, heavy rain, snow and ice. Hampshire Police in southern England said a man died after a tree fell onto a car on a major road near Winchester early in the day. Police in West Yorkshire said they were probing whether a second death from a traffic incident was linked to the storm. It is understood the road was not icy at the time of the incident. Storm Bert left at least 60,000 properties in Ireland without power, and closed
CONSPIRACIES: Kano suspended polio immunization in 2003 and 2004 following claims that polio vaccine was laced with substances that could render girls infertile Zuwaira Muhammad sat beside her emaciated 10-month-old twins on a clinic bed in northern Nigeria, caring for them as they battled malnutrition and malaria. She would have her babies vaccinated if they regain their strength, but for many in Kano — a hotbed of anti-vaccine sentiment — the choice is not an obvious one. The infants have been admitted to the 75-bed clinic in the Unguwa Uku neighbourhood, one of only two in the city of 4.5 million run by French aid agency Doctors Without Borders (MSF). Kano has the highest malaria burden in Nigeria, but the city has long
RSS